Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Completed 2

Sponsor Class

OTHER 4NIH 4INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Genitourinary 4Endocrine 1

Conditions

Prostatic Neoplasms 291Carcinoma, Renal Cell 172Kidney Neoplasms 118Urinary Bladder Neoplasms 102Breast Neoplasms 70Neoplasms 64Melanoma 48Testicular Neoplasms 45Sarcoma 45Wilms Tumor 44Lung Neoplasms 42Ovarian Neoplasms 41Neuroblastoma 39Colonic Neoplasms 34Lymphoma, Non-Hodgkin 32Lymphoma 31Osteosarcoma 28Neoplasm Metastasis 28Carcinoma, Non-Small-Cell Lung 28Pancreatic Neoplasms 26Neuroectodermal Tumors, Primitive, Peripheral 25Uterine Cervical Neoplasms 24Colorectal Neoplasms 23Carcinoma, Transitional Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Medulloblastoma 22Urethral Neoplasms 21Central Nervous System Neoplasms 21Carcinoma, Ovarian Epithelial 21Burkitt Lymphoma 21

Interventions

Erlotinib Hydrochloride 2Bevacizumab 2atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Contrast Media 1Botulinum Toxins, Type A 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Hereditary leiomyomatosis and renal cell cancer × Genitourinary × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT00001238 2026-05-22

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

National Institutes of Health Clinical Center (CC)

Recruiting
5,000 enrolled
EndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms, Pheochromocytoma

NCT01130519 2025-02-21

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
83 enrolled 17 charts
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms

NCT00971620 2017-04-07

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
18 enrolled 22 charts
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡